Imène Chentli

Imène Chentli

Auto-generated profile, based on publicly available information

Imène Chentli

Laboratoire de biologie et de génétique du cancer, Centre François Baclesse, Caen, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RLRaphael LEMAN
Raphael LEMAN
EMEtienne Muller
Etienne Muller
ALAngelina Legros
Angelina Legros
NGNicolas Goardon
Nicolas Goardon
ICImène Chentli
Imène Chentli
DVDominique Vaur
Dominique Vaur
Purpose: The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing of homologous recombination deficiency (HRD). However, in many countries, access to HRD testing is problematic and the failure rate is high. We developed an academic HRD test to support treatment decision-making. Experimental Design: Genomic Instability Scar (GIScar) was developed through targeted sequencing of a 127-gene panel to determine HRD status. GIScar was trained from a noninterventional study with 250 prospectively collected ovarian tumor samples. GIScar was validated on 469 DNA tumor samples from the PAOLA-1 trial evaluating maintenance olaparib for newly diagnosed ovarian cancer, and its predictive value was compared with Myriad Genetics MyChoice (MGMC). Results: GIScar showed significant correlation with MGMC HRD classification (kappa statistics: 0.780). From PAOLA-1 samples, more HRD-positive tumors were identified by GIScar (258) than MGMC (242), with a lower proportion of inconclusive results (1% vs. 9%, respectively). The HRs for progression-free survival (PFS) with olaparib versus placebo were 0.45 [95% confidence interval (CI), 0.33–0.62] in GIScar-identified HRD-positive BRCA-mutated tumors, 0.50 (95% CI, 0.31–0.80) in HRD-positive BRCA-wild-type tumors, and 1.02 (95% CI, 0.74–1.40) in HRD-negative tumors. Tumors identified as HRD positive by GIScar but HRD negative by MGMC had better PFS with olaparib (HR, 0.23; 95% CI, 0.07–0.72). Conclusions: GIScar is a valuable diagnostic tool, reliably detecting HRD and predicting sensitivity to olaparib for ovarian cancer. GIScar showed high analytic concordance with MGMC test and fewer inconclusive results. GIScar is easily implemented into diagnostic laboratories with a rapid turnaround.

25 November 2025
Verified
Other
Open access
RLRaphael LEMAN
Raphael LEMAN
EMEtienne Muller
Etienne Muller
ALAngelina Legros
Angelina Legros
NGNicolas Goardon
Nicolas Goardon
ICImène Chentli
Imène Chentli
DVDominique Vaur
Dominique Vaur
Kaplan–Meier estimates of PFS stratified on Giscar HRD status among inconclusive status of MGMC (n = 43).


25 November 2025
Verified
Other
Open access
RLRaphael LEMAN
Raphael LEMAN
EMEtienne Muller
Etienne Muller
ALAngelina Legros
Angelina Legros
NGNicolas Goardon
Nicolas Goardon
ICImène Chentli
Imène Chentli
DVDominique Vaur
Dominique Vaur
PFS in patients according to GIScar (left panel) and MGMC scores (right panel).

25 November 2025
Verified
Other
Open access
RLRaphael LEMAN
Raphael LEMAN
EMEtienne Muller
Etienne Muller
ALAngelina Legros
Angelina Legros
NGNicolas Goardon
Nicolas Goardon
ICImène Chentli
Imène Chentli
DVDominique Vaur
Dominique Vaur
Kaplan–Meier estimates of PFS stratified on treatment arm (n = 469).